NASDAQ · SLDB
Solid Biosciences Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SLDB: Nov 2, 2026
Solid Biosciences Inc. Common Stock is estimated to report earnings on 11/02/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.37. The reported EPS for the same quarter last year was $-0.48.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.37 | $-0.34 | $-0.38 | 4 |
| Dec 2026 | $-0.37 | $-0.34 | $-0.38 | 4 |
| Mar 2027 | $-0.38 | $-0.35 | $-0.40 | 4 |
| Jun 2027 | $-0.37 | $-0.33 | $-0.40 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks- RTTNews · Oct 26, 1:13 PM EDTSolid Biosciences Receives EU Orphan Drug Designation For SGT-212 In Friedreich's Ataxia(RTTNews) – Solid Biosciences Inc. (SLDB) announced that the European Commission has granted Orphan Medicinal Product designation to SGT-212, an investigational gene therapy being developed to treat Friedreich's ataxia (FA), a rare inherited disease that causes progressive neurol
- Fintel · Oct 16, 5:41 PM EDTUBS Initiates Coverage of Solid Biosciences at BuyFintel reports that on October 15, 2026, UBS initiated coverage of Solid Biosciences (NASDAQGS:SLDB) with a Buy recommendation. Prior to this rating action, the stock closed at $5.46 on October 14, 2026. On October 15, 2026, the latest close was recorded at $5.74. Over a one-week
- Fintel · Sep 16, 5:57 PM EDTRBC Capital Initiates Coverage of Solid Biosciences at OutperformFintel reports that on September 16, 2026, RBC Capital initiated coverage of Solid Biosciences (NASDAQGS:SLDB) with a Outperform recommendation. This initiation of coverage by RBC Capital occurred on September 16, 2026, following a period of market activity where the stock closed
- RTTNews · Jul 6, 9:13 AM EDTAre More Solid Gains On The Horizon For SLDB?(RTTNews) – Although the idea of gene therapy was first proposed in the 1960s, it took many years of research before it became a reality. In 2017, the first gene therapy – Novartis' Kymriah – was approved for the treatment of children and young adults with a type of blood cancer
- RTTNews · Apr 28, 11:44 AM EDTEuropean Commission Grants Orphan Drug Designation To Solid Biosciences' SGT-003 For DMD(RTTNews) – Solid Biosciences Inc. (SLDB), a life sciences company, on Tuesday announced receipt of an Orphan Drug Designation from the European Commission for SGT-003 in treating Duchenne's muscular dystrophy.
- Fintel · Mar 20, 8:04 PM EDTGuggenheim Initiates Coverage of Solid Biosciences (SLDB) with Buy RecommendationFintel reports that on March 20, 2026, Guggenheim initiated coverage of Solid Biosciences (NasdaqGS:SLDB) with a Buy recommendation. Analyst Price Forecast Suggests 128.19% Upside
- RTTNews · Feb 9, 9:42 AM ESTSolid Biosciences To Dose First Patient In IMPACT DUCHENNE Phase 3 Trial In Q1'26(RTTNews) – Solid Biosciences Inc. (SLDB) announced that it has received positive regulatory feedback from a recent Type C meeting with the U.S FDA, marking a key step forward for its gene therapy candidate SGT-003 in Duchenne muscular dystrophy.
- Zacks · Jan 16, 9:08 AM ESTWill KROS Stock's Restructuring Efforts Reap Rewards for Investors?Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 2026 with cash runway into 2028.
- RTTNews · Jan 13, 12:54 AM ESTSolid Biosciences Secures FDA Orphan Drug Nod For SGT-212 In Friedreich's Ataxia(RTTNews) – Solid Biosciences Inc. (SLDB), a neuromuscular and cardiac disease medicine developer, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to SGT-212 for the treatment of Friedreich's ataxia or FA.
- RTTNews · Dec 17, 11:15 PM ESTBiotech Momentum Carries After-Hours Trading Gains(RTTNews) – Several small- and mid-cap stocks posted notable gains in Wednesday's after-hours trading session, even though most companies did not release fresh news. The movement was largely driven by investor sentiment and sector momentum.
- Fintel · Dec 4, 3:00 PM ESTNeedham Initiates Coverage of Solid Biosciences (SLDB) with Buy RecommendationFintel reports that on December 4, 2025, Needham initiated coverage of Solid Biosciences (NasdaqGS:SLDB) with a Buy recommendation. Analyst Price Forecast Suggests 198.07% Upside
- Fintel · Nov 4, 7:12 PM ESTChardan Capital Maintains Solid Biosciences (SLDB) Buy RecommendationFintel reports that on November 4, 2025, Chardan Capital maintained coverage of Solid Biosciences (NasdaqGS:SLDB) with a Buy recommendation. Analyst Price Forecast Suggests 266.28% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Solid Biosciences Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.